ArticleJournal of oral biology and craniofacial research
Exploring the predictive power of antinuclear antibodies and Rheumatoid factor correlations in anticipating therapeutic outcomes for female patients with coexisting Sjögren's syndrome and Rheumatoid arthritis.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sjögren's Syndrome (SS) and Rheumatoid Arthritis (RA) are autoimmune conditions that often coexist in female patients. Biomarkers such as antinuclear antibodies (ANA) and rheumatoid factor (RF) are used for diagnosis, but their predictive power for treatment outcomes remains unclear. This study aims to investigate the correlation between age, ANA, RF, and treatment response in female patients with both SS and RA. Objective: To evaluate the relationships between age, ANA, RF levels, RA (disease present), and treatment response using Pearson correlation analysis and a neural network model, to predict treatment outcomes in patients with coexisting SS and RA. Methods: A cohort of 56 female patients aged 30-73 was analyzed. Descriptive statistics provided an overview of key variables, followed by Pearson correlation analysis to assess relationships between age, ANA, RF, RA, and treatment response. A neural network model was developed to predict treatment response based on age, ANA, and RF levels, using a training-to-testing split of 81.3 % and 18.8 %, respectively. Results: The Pearson correlation analysis revealed a significant positive correlation between age and ANA levels (r = .541, p = 0.031), though no significant correlations were found between age, RF, RA, and treatment response. The neural network model achieved an accuracy of 92.3 % during training and 100 % accuracy during testing for most treatment categories. However, the model struggled to accurately distinguish between certain classes, particularly treatment categories 1 and 3. Conclusion: Age showed a significant correlation with ANA levels, indicating that older patients may have elevated ANA. The neural network model demonstrated strong predictive power for treatment response, although further refinement is needed to improve its ability to distinguish between all response categories. These findings suggest that machine learning models could enhance personalized treatment strategies for patients with SS and RA, but additional validation with larger datasets is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.